CLASP flyer

	Stanford / VA / NIA Aging Clinical Research Center Palo Alto Veterans Health Care System 3801 Miranda Ave 151Y, Palo Alto, CA 94304 Phone: 650-852-3287 Fax: 650-852-3297 http://alzheimer.stanford.edu
	Home \| About the ACRC \| Research \| Educational Videos \| Geriatric Depression Scale \| Collaborators \| Additional Resources \| Contact \| Links

Can Cholesterol-Lowering Drugs Help Slow Alzheimer’s Disease?

Give us a hand in finding out.

Cholesterol lowering drugs (also called “statins”) are effective weapons in the fight against heart disease. Now, some evidence suggests that statins also may be able to slow the devastating effects of Alzheimer’s disease (AD) on the brain.

The Alzheimer’s Disease Cooperative Study, a group of research centers sponsored by the U.S. Government’s National Institute on Aging, is launching the CLASP-AD (Cholesterol Lowering Agent to Slow Progression of AD) research study to find out more about the effect on AD of one statin, called simvastatin (Zocor).

The CLASP-AD study is looking for volunteers who:

have mild to moderate AD
are age 50 or older
speak English or Spanish
do not currently take or need cholesterol lowering drugs
have a study partner – a friend or relative who can accompany the volunteer to all clinic visits and answer questions about him/her.

CLASP-AD is a randomized, placebo-controlled research study. Half of participants will be assigned at random to receive the experimental drug, the other half will receive placebo (inactive pill). Participants will be assessed regularly by physicians and qualified health care professionals during the 21-month study.
For more information, or to inquire about participating, contact: Alena Kleytman at (650) 849-0339 or Email